C

Community Clinical Research, Inc. | Austin, TX

Research site

(Unclaimed)

Location

8334 Cross Park Drive, Austin, Texas, United States of America

Site insights

Top conditions

Top treatments

Aripiprazole

KarXT

Lurasidone

BI 409306

Rapastinel

LY03004

Risperidone

Armodafinil

BHV-7000

Brexpiprazole

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 83 total trials

A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia

This is a Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Determine the the Efficacy and Safety of SEP-363856 in Acutely...

Enrolling

Schizophrenia

Drug: SEP-363856

Other: Placebo

An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

This is a Phase 3, multicenter, 52-week, outpatient, open-label extension (OLE) study to evaluate the long-term safety and tolerability of adjunctive...

Enrolling

Schizophrenia

Drug: Xanomeline and Trospium Chloride Capsules

Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)

In this study, an investigational medication named BXCL501 is being tested for the treatment of episodes of agitation associated with bipolar I and b...

Active, not recruiting

Schizophreniform Disorders

Bipolar II Disorder

Drug: BXCL501

Drug: Matching Placebo

Study to Evaluate Efficacy and Safety of Ropanicant in MDD Patients

The primary objective is to evaluate the efficacy of Ropanicant at two different dosage levels compared to placebo in patients with Major Depressive...

Enrolling

Major Depressive Disorder (MDD)

Drug: Placebo

Drug: Ropanicant